“…In humans, chronic diseases such as chronic heart failure, hypertension and Parkinson’s disease are characterised by low plasma concentration and tissue CoQ 10 content, with CoQ 10 supplementation shown to improve clinical responses to treatment (Hofman-Bang, Rehnqvist, Swedberg, Wiklund, & Åström, 1995; Jankowski, Korzeniowska, Cieślewicz, & Jabłecka, 2016; Mortensen et al, 2014; Yang et al, 2015). Healthy human athletes have also been found to develop CoQ 10 deficiencies, believed to be due to increased metabolic demand (Cooke et al, 2008; M. Kon et al, 2007; Orlando et al, 2018; Zhou, Zhang, Davie, & Marshall-Gradisnik, 2005). Deficiencies in skeletal muscle CoQ 10 are thought to result in less efficient energy transduction due to decreased ETC activity and suboptimal ATP production (Lenaz et al, 1999), resulting in reduced effective skeletal muscle contractile function and earlier onset of fatigue (Cooke et al, 2008; M. Kon et al, 2007; Michihiro Kon et al, 2008; Kwong et al, 2002; Mizuno et al, 2008).…”